Open access
Aug 2026
Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series
Data support anti-CD19 CAR T cell therapy as a durable, effective intervention for refractory MG and warrant further evaluation in prospective controlled clinical trials.
T. Hegelmaier, J. Motte, Denise Walther et al.
· Cell Reports Medicine · 0 citations